Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) have been given an average recommendation of “Moderate Buy” by the twelve analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $160.27.

Several brokerages have recently commented on ASND. Oppenheimer upped their target price on Ascendis Pharma A/S from $144.00 to $150.00 in a report on Thursday, November 3rd. Morgan Stanley upped their target price on Ascendis Pharma A/S from $146.00 to $148.00 and gave the company an “overweight” rating in a report on Tuesday, November 15th. Cantor Fitzgerald reduced their target price on Ascendis Pharma A/S from $184.00 to $182.00 in a report on Thursday, October 27th. Citigroup upped their price target on Ascendis Pharma A/S from $157.00 to $163.00 and gave the company a “buy” rating in a research report on Thursday, November 3rd. Finally, Wedbush upped their price target on Ascendis Pharma A/S from $151.00 to $164.00 and gave the company an “outperform” rating in a research report on Monday, November 14th.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its position in shares of Ascendis Pharma A/S by 6.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,165,375 shares of the biotechnology company’s stock worth $480,173,000 after acquiring an additional 295,224 shares during the period. Wellington Management Group LLP lifted its position in shares of Ascendis Pharma A/S by 14.6% in the 1st quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company’s stock worth $547,552,000 after acquiring an additional 594,855 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Ascendis Pharma A/S by 89.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 3,316,215 shares of the biotechnology company’s stock worth $308,275,000 after acquiring an additional 1,561,757 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Ascendis Pharma A/S by 41.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,184,356 shares of the biotechnology company’s stock worth $122,296,000 after acquiring an additional 349,157 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Ascendis Pharma A/S by 1.4% in the 1st quarter. Invesco Ltd. now owns 1,017,090 shares of the biotechnology company’s stock worth $119,365,000 after acquiring an additional 14,047 shares during the period.

Ascendis Pharma A/S Trading Down 2.4 %

Shares of Ascendis Pharma A/S stock opened at $115.03 on Friday. The company has a quick ratio of 6.83, a current ratio of 7.56 and a debt-to-equity ratio of 1.18. The firm has a market cap of $6.56 billion, a price-to-earnings ratio of -12.49 and a beta of 0.54. The business has a fifty day simple moving average of $119.48 and a 200-day simple moving average of $106.10. Ascendis Pharma A/S has a fifty-two week low of $61.58 and a fifty-two week high of $134.52.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($3.05) earnings per share for the quarter, missing the consensus estimate of ($2.52) by ($0.53). Ascendis Pharma A/S had a negative net margin of 1,473.30% and a negative return on equity of 71.44%. The firm had revenue of $15.41 million during the quarter, compared to analyst estimates of $10.67 million. On average, equities analysts forecast that Ascendis Pharma A/S will post -9.17 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

(Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Further Reading

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.